Hyperlipidemia after liver transplantation: Natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin

Transplantation

Volumn 62, Issue 7, 1996, Pages 934-942

  Imagawa, David K ^a   Dawson III, Sherfield ^a   Holt, Curtis D ^a   Kirk, Pamela S ^a   Kaldas, Fady M ^a   Shackleton, Christopher R ^a   Seu, Philip ^a   Rudich, Steve M ^a   Kinkhabwala, Milan M ^a   Martin, Paul ^a   Goldstein, Leonard I ^a   Murray, Natalie G B ^a   Terasaki, Paul I ^a   Busuttil, Ronald W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRAVASTATIN; TACROLIMUS;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; RHABDOMYOLYSIS;

ADULT; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LIPIDS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PRAVASTATIN; PROSPECTIVE STUDIES;

EID: 10244221059     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199610150-00011     Document Type: Article

References (36)

1. Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis 1991; 18: 353.
2. Ong CS, Pollock CA, Caterson RJ, Mahony JF, Waugh DA, Ibels LS. Hyperlipidemia in renal transplant recipients: natural history and response to treatment. Medicine 1994; 73: 215.
3. Miller LW, Schlant RC, Kobashigawa JA, Kubo S, Renlund DG. 24th Bethesda Conference: cardiac transplantation. Task force 5: complications. J Am Coll Cardiol 1993; 22: 41.
4. Eich D, Thompson JA, Ko DJ, et al. Hypercholesterolemia in long-term survivors of heart transplantation: an early marker of accelerated coronary artery disease. J Heart Lung Transplant 1991; 10: 45.
5. Munoz SJ, Deems RO, Moritz MJ, Martin P, Jarrell BE, Maddrey WC. Hyperlipidemia and obesity after orthotopic liver transplantation. Transplant Proc 1991; 23: 1480.
6. McDiarmid SV, Gornbein JA, Fortunat M, et al. Serum lipid abnormalities in pediatric liver transplant patients. Transplantation 1992; 53: 109.
7. Mathe D, Adam R, Malmendier C, et al. Prevalence of dyslipidemia in liver transplant patients. Transplantation 1992; 54: 167.
8. Jindal RM, Popescu I, Emre S, et al. Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506. Transplantation 1994; 57: 1395.
9. Kasiske BL, Tortorice KL, Heim-Duthoy KL, et al. Lovastatin treatment of hypercholesterolemia in renal transplant recipients. Transplantation 1990; 49: 95.
10. Castelao AM, Grino JM, Andres E, et al. HMGCoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation. Transplant Proc 1993; 25: 1043.
11. Goldberg RB, Roth D. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine. Am J Cardiol 1995; 76: A107.
12. Li PKT, Mak TWL, Chan TH, Wang A, Lam CWK, Lai KN. Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia. Transplantation 1995; 60: 652.
13. Kainuma O, Asano T, Ochiai T, Isono K. Lipid disorders in renal transplant recipients. Transplant Proc 1992; 24: 1585.
14. Al'Halawani MH, Larsen JL, Miller S, Frisbie K, Taylor RJ, Stratta RJ. Pravastatin reduces serum cholesterol and low density lipoprotein concentrations following pancreas transplantation. Transplantation 1994; 58: 1204.
15. Katznelson A, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation - a pilot study. Transplantation 1996; 61: 1469.
16. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333; 621.
17. Vanhaecke J, Van Cleemput J, Van Lierde JV, Daenen W, De Geest H. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation 1994; 58: 42.
18. Grundy SM. National Cholesterol Education Program: second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation 1994; 89: 1333.
19. Wang XM, Terasaki PI, Rankin GW Jr, et al. A new microcellular cytotoxicity test based on calcein AM release. Hum Immunol 1993; 37: 264.
20. Krentz AJ, Cramb R, Dousset B, et al. Serum lipids and apolipoproteins in liver transplant recipients: a comparative study of cyclosporin A and FK 506. J Lab Clin Med 1994; 124: 381.
21. US Multicenter FK 506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110.
22. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys. JAMA 1993; 269: 3002.
23. Harris KGP, Russel GI, Parvin SD, Veitch PS, Walls J. Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients. Br Med J 1986; 292: 16.
24. Keogh A, Simons L, Spratt P, et al. Hyperlipidemia after heart transplantation. J Heart Transplant 1988; 7: 171.
25. Cattran DC, Steiner G, Wilson DR, Fenton SSA. Hyperlipidemia after renal transplantation: natural history and pathophysiology. Ann Intern Med 1979; 91: 554.
26. Harris KPG, Russel GI, Parvin SP, Veitch PS, Walls J. Metabolic effects of conversion from cyclosporin to azathioprine in renal transplant recipients. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1984; 21: 1010.
27. Ballantyne CM, Podet EJ, Patsch WP, et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989; 262: 53.
28. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425.
29. Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use: report of two cases in cardiac transplant recipients. JAMA 1988; 260: 239.
30. Regazzi MB, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993; 25: 2732.
31. Cutts JL, Bankhurst AD. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2. J Cell Physiol 1990; 145: 244.
32. McPherson R, Tsoukas C, Baines MG, et al. Effects of lovastatin on natural killer cell function and other immunological parameters in man. J Clin Immunol 1993; 13: 439.
33. Sinensky M, Beck LA, Leonard S, Evans R. Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem 1990; 265: 19937.
34. Kiessling R, Hochman PS, Haller O, Shearer GM, Wigzel H. Evidence for a similar or common mechanism for natural killer cell activity and resistance to haemopoietic grafts. Eur J Immunol 1977; 7: 655.
35. Lewis CE, McGee JO, eds. The natural killer cell. New York: Oxford University Press, 1992: 175.
36. Nemlander A, Saksela E, Hayry P. Are "natural killer" cells involved in allograft rejection? Eur J Immunol 1983; 13: 348.